

**LASA SUPERGENOMICS LIMITED**

CORPORATE OFFICE: B/207, City Point, Near Kohinoor Hotel, J B Nagar (Chakala)
Metro Station, Andheri (E), Mumbai – 400059, Maharashtra, India,
Tel: 022-4970 1092, Email: mail@lasalabs.com, Website: www.lasalabs.com

Ref. No.: LASA/SE/19-20/46

Monday, February 10, 2020

To, Corporate Services Department BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001. BSE CODE –540702	To, Corporate Services Department National Stock Exchange of India Limited “Exchange Plaza”, Plot No. C/1, G Block Bandra-Kurla Complex, Bandra (E), Mumbai – 400 051. NSE CODE: LASA
---	---

Dear Sir/Madam,

Sub. : Outcome of Board Meeting held today i.e 10 February, 2020

Pursuant to Regulation 29 and 30 of SEBI (Listing obligation and disclosure requirements) Regulations, 2015, we would like to inform you that the Board of Directors in their meeting held today at the Corporate Office of the Company which was commenced at 1.00 p.m. and concluded at 3.45 p.m. have considered, approved and took on record the Unaudited Financial Results for the quarter and nine months ended December 31,2019.

A copy of the statement of Unaudited Financial Results along with Limited Review Report submitted by the Statutory Auditors of the Company is attached herewith.

The above information is also available on the company's website at www.lasalabs.com and on the website of the stock Exchange at www.bseindia.com and www.nseindia.com.

Please take the above on your records.

Thanking You

For Lasa Supergenomics Limited



Nidhi Kulshreshtha

Company Secretary and Compliance Officer

Encl: as above.

Statement of Unaudited Financial Results for the Quarter and Nine months ended 31 December, 2019

(Rs. In Lakhs)

Particulars	Quarter ended			Nine Months Ended		Year ended
	31.12.2019 (Unaudited)	30.09.2019 (Unaudited)	31.12.2018 (Unaudited)	31.12.2019 (Unaudited)	31.12.2018 (Unaudited)	31.03.2019 (Audited)
1. INCOME						
a. Revenue from Operations	3,928.97	4,041.19	5,388.38	11,868.56	12,754.92	16,957.30
b. Other Income	31.95	5.24	88.34	46.36	294.20	47.45
Total Income	3,960.91	4,046.44	5,476.72	11,914.92	13,049.12	17,004.75
2. Expenses						
a. Cost of Materials consumed	1,931.24	1,917.67	2,606.24	6,157.41	6,091.86	8,380.65
b. Cost of Traded Goods	-	-	1,582.40	49.41	3,356.31	4,240.38
c. Change in Inventories of Finished Goods, Work-in-Progress and Stock in trade	245.85	481.18	500.29	1,026.91	357.36	173.62
d. Employee benefits expenses	350.80	349.08	297.71	999.51	851.86	1,173.51
e. Finance costs	174.07	199.98	193.77	588.07	952.45	837.88
f. Depreciation & amortizations expenses	439.65	432.20	487.22	1,298.08	1,452.42	1,930.85
g. Other Expenses	584.65	542.49	464.64	1,564.99	1,294.08	1,878.14
Total Expenses (a to g)	3,726.26	3,922.60	6,132.27	11,684.38	14,356.33	18,615.03
Exceptional Items	-	-	-	-	-	-
3. Profit / (Loss) before tax (1-2)	234.65	123.83	(655.55)	230.54	(1,307.21)	(1,610.28)
4. Tax expense						
Current Tax	42.54	-	-	42.54	-	-
Deferred Tax	(102.28)	169.03	(127.68)	46.42	(354.83)	(468.17)
Short / Excess income tax provision for earlier years	36.75	-	-	36.75	70.69	60.95
5. Net Profit / (Loss) after tax (3-4)	257.65	(45.20)	(527.86)	104.83	(1,023.07)	(1,203.06)
6. Other Comprehensive Income						
Items that will not be reclassified into Profit or Loss						
- Remeasurement of Defined Benefit Plans (Net of tax)	-	-	-	-	(0.38)	(1.25)
7. Total Comprehensive Income for the year (after tax) (5+6)	257.65	(45.20)	(527.86)	104.83	(1,023.45)	(1,204.31)
8. Paid-up Equity Share Capital (Face Value of Re. 10/- each)	4,067.27	2,286.44	2,286.44	4,067.27	2,286.44	2,286.44
9. Other Equity excluding Revaluation reserve as per Balance Sheet						
	-	-	-	-	-	8,243.34
10. Earnings per Equity Share (of Rs. 10/- each)						
(a) Basic	0.89	(0.20)	(2.31)	0.42	(4.47)	(5.26)
(b) Diluted	0.89	(0.20)	(2.31)	0.42	(4.47)	(5.26)

Notes :

1) The Above Financial Results were reviewed by the audit committee of the board on 10th February, 2020 and approved by the Board of Directors of the company at their meeting held on same date. The Statutory auditors have expressed on unmodified opinion. The review report has been filed with stock exchange and is available on the company's website. The Financial results have been prepared in accordance with Ind AS notified under the Companies (Accounting Standards) Rule, 2015.

2) Other income includes Rs.7.56 lakhs being the net amount of interest reversed on the account of the component of unsecured loan of earlier periods as the same now has been repaid.

3) Company has issued and allotted 1,78,08,219 Equity Shares of Rs.10 each at Rs.18.25/-per share including Rs.8.25 on account of share premium on 30th November 2019 to the promoter of the company Dr. Omkar Pravin Herlekar.

4) Finance cost includes Gain / (Loss) on account of foreign exchange fluctuations

Quarter / Half year ended	31.12.2019	30.09.2019	31.12.2018	31.12.2019	31.12.2018	31.03.2019
Foreign Exchange Gain / (Loss)	(15.46)	(46.08)	79.71	(52.76)	(159.73)	(151.16)

5) The Company has single business segment i.e. Active Pharmaceutical Ingredients (API), therefore, in the context of Ind As 108, disclosure of segment information is not applicable.

6) Figures of previous period have been re-grouped / reclassified wherever necessary, to confirm to this period's classification.

By order of the Board of Directors
For Lasasupergenerics Limited

Omkar Herlekar
Chairman & Managing Director
(DIN No. 01587154)



Place : Mumbai
Date : 10th February, 2020

CIN : L24233MH2016PLC274202



LIMITED REVIEW REPORT

To,
**THE BOARD OF DIRECTORS
LASA SUPERGENRICS LIMITED**

1. We have reviewed the accompanying Statement of Unaudited Financial Results of **Lasa Supergenrics Limited** ("the Company") for the quarter ended December 31, 2019 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. The figures up to the quarter ended were only reviewed and not subjected to audit. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.
2. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, 'Review of Interim Financial information performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the applicable Indian Accounting Standards (Ind AS) as prescribed under section 133 of Companies Act, 2013 read with rules issued there under and other recognised accounting practices and principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligation And Disclosure Requirements) Regulation, 2015 as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Thanawala & Company

Chartered Accountants

Firm Registration No.: 110948W

h w
CA Vijay Thanawala
(Proprietor)

Membership No.: 15632

Place: Mumbai,

Date: 10/02/2020



UDIN - 20015632AAAAAF6446